GSE147876 GSE147877 enzalutamide MR42D 4 v 3 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE147876_GSE147877_enzalutamide_MR42D_4_v_3_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE147876_GSE147877_enzalutamide_MR42D_4_v_3_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE147876_GSE147877_enzalutamide_MR42D_4_v_3_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE147876_GSE147877_enzalutamide_MR42D_4_v_3_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

acetylserotonin O-methyltransferase like

Gene

synergin gamma

Gene

H2A clustered histone 11

Gene

long intergenic non-protein coding RNA 665

Gene

MT-CO2 pseudogene 12

Gene

oligodendrocyte maturation-associated long intergenic non-coding RNA

Gene

CD27 antisense RNA 1

Gene

MT-ND2 pseudogene 28

Gene

ZNF528 antisense RNA 1

Gene

colorectal cancer associated 1

  • Gene

    acetylserotonin O-methyltransferase like



  • Gene

    H2A clustered histone 11


  • Gene

    long intergenic non-protein coding RNA 665


  • Gene

    MT-CO2 pseudogene 12


  • Gene

    oligodendrocyte maturation-associated long intergenic non-coding RNA


  • Gene

    CD27 antisense RNA 1


  • Gene

    MT-ND2 pseudogene 28


  • Gene

    ZNF528 antisense RNA 1


  • Gene

    colorectal cancer associated 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.